Blood Glucose Test Systems in Canada vs the US: Which Class Applies?

October 1, 2026

CliniEco graduated leak-proof specimen cup with a screw cap for clinic sample collection

Quick facts

A glucose test system measures glucose quantitatively in blood and other body fluids, and the measurement is used in the diagnosis and treatment of carbohydrate metabolism disorders.
United States: 21 CFR 862.1345 places the device in Class II with special controls. Only the form intended solely as a drink to test glucose tolerance is exempt from premarket notification.
Canada: the system is an in vitro diagnostic device, and the class depends on where it is used. An IVDD intended for use outside a laboratory — at home or at the point of care — is a near patient IVDD, and Part 2 Rule 6 of Schedule 1 to the Medical Devices Regulations, SOR/98-282 classifies it as Class III.
A glucose system used inside a testing laboratory is classified under the patient-management rules instead, and lands in Class II.
Rule 9 of Part 2 carves a small number of near-patient devices down to Class II. Pregnancy and fertility testing, and cholesterol determination, are named. Glucose is not.
Canadian regulation text used here is current to 2026-09-21 and last amended 2026-06-17, as stated on the official consolidation.

Blood glucose is the most widely performed near-patient test in health care, and it is the clearest illustration of how a Canadian rule can produce a class that an American catalogue section does not. The two systems are asking different questions. The United States asks what the device measures and places it in Class II. Canada asks where the device is used, and a device used outside a laboratory is a near patient IVDD in Class III. This article sets out both routes, the short list of near-patient carve-outs, and what a clinic or laboratory should hold on file.

What is a glucose test system in each classification system?

The American identification paragraph is precise about the measurand and the clinical context. Section 862.1345(a) describes a glucose test system as a device intended to measure glucose quantitatively in blood and other body fluids, and states that glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

The classification paragraph then places the device in Class II with special controls and grants a single narrow exemption: the device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from premarket notification subject to the limitations in section 862.9.

Canada does not classify the system by a named entry. It treats the device as an in vitro diagnostic device, and two definitions set up the answer:

In vitro diagnostic device — a medical device intended to be used in vitro for the examination of specimens taken from the body.
Near patient IVDD — an IVDD intended for use outside a laboratory, for testing at home or at the point of care, such as a pharmacy, a health care professional's office or the bedside.

With those definitions in hand, the class follows from where the device is used.

How does the glucose system class differ between Canada and the United States?

The divergence is not in what the device measures. It is in where it runs.

Item	Canada	United States
Named entry	None; classified as an IVDD	21 CFR 862.1345
Class for a laboratory analyser	Class II, under the patient-management rules	Class II with special controls
Class for a home or point-of-care system	Class III, as a near patient IVDD under Part 2 Rule 6	Class II with special controls
Basis for the class	Where the test is run	What the device measures
Premarket position	Licence class follows the rule	Premarket notification, unless the tolerance-drink exemption applies
Special controls concept	Not a Canadian mechanism	Stated in the section

The Canadian near-patient rule is short and does not distinguish between one analyte and another. Part 2 Rule 6 of Schedule 1 states that a near patient IVDD is classified as Class III. The definition of a near patient IVDD is what pulls a home meter and a pharmacy counter meter into that rule: both are intended for use outside a laboratory.

A bench analyser in an accredited laboratory answers a different question. It is not intended for use outside a laboratory, so Rule 6 does not reach it, and the class is derived from the patient-management rules instead, where an IVDD used for patient management is Class II unless a listed exception applies.

Benchtop laboratory incubator with digital temperature display used to hold specimens

Which near-patient devices does Canada carve out of the Class III rule?

The carve-outs are short, and glucose is not among them. Part 2 Rule 9 replaces the general result for the devices in its table.

Near-patient device	Canada (Part 2 Rule 9)	United States
Detection of pregnancy or fertility testing	Class II	862.1155, Class II for early pregnancy detection
Determining cholesterol level	Class II	Clinical chemistry section, Class II
Blood glucose measurement	Not listed; Part 2 Rule 6 applies, Class III	862.1345, Class II
Blood grouping or tissue typing	Class III under Part 2 Rule 5	Blood bank reagents, Class II or III by use
Microbiology media to identify an organism	Class I under Part 2 Rule 9	Culture media sections, Class I

The drafting is deliberate. Rule 9 opens with the words "Despite rules 1 to 8", which is how it can lower a device that Rule 6 would otherwise put in Class III. Only the devices in the table receive that treatment. Everything else that meets the near-patient definition stays in Rule 6.

For a diabetes program this has a concrete consequence. The same test that a laboratory runs as a Class II device becomes a Class III device when it is moved to the bedside, the pharmacy counter or the patient's home, and the class follows the placement rather than the chemistry.

Do Canada and the United States regulate a home glucose meter the same way?

They do not, and the difference is durable rather than incidental.

The American classification was set around the measurand. A glucose test system is a Class II device with special controls wherever it is used, whether it sits on a laboratory bench or on a kitchen table. The special controls attach to the generic type and travel with it.

The Canadian classification was set around the setting of use. The Medical Devices Regulations were amended in 2007 to address devices used outside central laboratories, and the near-patient rule was the instrument. A home meter is the paradigm case that rule was written for.

For an institution that operates both a laboratory and a point-of-care program, the practical effect is that the same analyte can carry two different classes inside one Canadian organisation, depending only on where the test is performed.

A buyer or quality lead who wants to check a specific product can look up the American entry in the openFDA device classification API or the FDA classification database. On the Canadian side the class follows from the rule, and the rule text is the reference to keep rather than a product lookup.

What should a point-of-care program keep on file?

Six items, and the first is the one that fixes the class.

The setting of use for each device. Whether the meter is used in the laboratory or at the point of care determines the rule that applies in Canada.
The maker's intended use statement. The near-patient definition turns on the maker's stated intended use, not the operator's habits.
The licence or clearance position. In Canada, the class and licence status; in the United States, the position under the glucose test system section.
The quality-control record. Controls, calibration and the frequency at which they are run belong with the device file.
The operator competency record. Where a non-laboratory operator runs the test, the competency record supports the program.
The result and action log. The record should show what happened when a result fell outside the acceptable range.

Which consumables does a laboratory or clinic restock alongside its testing lines?

A specimen collection bench restocks containers, pipettes, transport packaging and disposables on the same cycle as its analysers. For practices buying at case level, the wholesale ordering page sets out account and case terms, and the B2B wholesale collection lists the lines held for institutional buyers. The graduated specimen cups cover sample collection, the laboratory consumables pack with parafilm and pipettes covers bench handling, and programs that also run culture work can start with the sterilization monitoring collection or the biological indicator 5-pack trial.

Sources

Related reading

CliniEco Medical supplies eye care, laboratory and clinic consumables of the kind described in this article. MDEL #35334. This article is written for laboratory, procurement and infection-control professionals and is not clinical guidance; test selection, quality control and result interpretation belong to the laboratory director and the provincial requirements that apply to the facility.

Frequently Asked Questions

What class is a blood glucose test system in the United States?

Class II with special controls under 21 CFR 862.1345. Only the form intended solely for use as a drink to test glucose tolerance is exempt from premarket notification, subject to the limitations in 21 CFR 862.9.

What class is a blood glucose test system in Canada?

It depends on where the device is used. A system used inside a testing laboratory is classified under the patient-management rules and is Class II. A system intended for use outside a laboratory, at home or at the point of care, is a near patient IVDD and is Class III under Part 2 Rule 6 of Schedule 1.

What counts as a near patient IVDD in Canada?

An in vitro diagnostic device intended for use outside a laboratory, for testing at home or at the point of care, such as a pharmacy, a health care professional's office or the bedside. The definition is set out in the Medical Devices Regulations.

Are any near-patient devices carved out of the Class III rule?

Yes, a short list in Part 2 Rule 9 of Schedule 1. It names near-patient devices for the detection of pregnancy or for fertility testing, and for determining cholesterol level, and places both in Class II. Blood glucose measurement is not in that table.

Why is the same test a different class in the two countries?

Because the two systems ask different questions. The United States classifies by what the device measures and places a glucose test system in Class II wherever it is used. Canada classifies by where the device is used, and a near-patient IVDD is Class III unless it appears in the Rule 9 table.

Does the Canadian rule apply to a laboratory analyser as well?

No. The near-patient rule reaches only devices intended for use outside a laboratory. An analyser used inside a testing laboratory is classified instead under the patient-management rules, where an IVDD used for patient management is Class II unless a listed exception applies.